Anticoagulation

MARINER: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk.
Sponsor: Jansen Research & Development, LLC

[hr]

Asthma

LIBERTY: A randomized, double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Dupilumab in patients with persistent asthma.
Sponsor: Sanofi

[hr]

Septic Shock

SSAIL: Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148.
Sponsor: Leading BioSciences, Inc

[hr]

Interstial Lung Disease

BRAVE: Study of the use of novel gene identifiers in bronchoscopy sample specimens for the diagnosis of interstitial lung disease.
Sponsor: Veracity

[hr]

COPD

Impact: A Phase III study to effect the effect of triple combination therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on COPD patients with a history of COPD exacerbations. 
Sponsor: GSK

> Galathea

Randomized, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations.
Sponsor: Astra Zeneca

[hr]